Members of a key reimbursement policy panel on December 6 continued to push for the creation of separate generic price bands for both middle and lower bands under the current three price-band grouping rule as a way to address unreasonable…
HOME > FY2019 H1 Earnings
FY2019 H1 Earnings
-
8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
-
Bullish New Drugs Mitigated Vesicare/Tarceva Patent Cliff: Astellas CEO
November 1, 2019
-
Daiichi Sankyo Ramps Up R&D Investment for ADC, 16 Studies Added to DS-8201
November 1, 2019
-
Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
-
Despite a Hold by Key Panel, Ono Sees Cachexia Drug Launch in April-September 2020
November 1, 2019
-
Xtandi Helps Astellas Counter Vesicare/Tarceva LOEs in April-September
November 1, 2019
-
Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
-
Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
-
Shionogi’s Half-Year Sales Slip 4.4% after Xofluza Milestone Gain
October 31, 2019
-
Mitsubishi Tanabe to Give Another Try for Radicava’s EU OK, but in Oral Form: Chief
October 31, 2019
-
Mitsubishi Tanabe Suffers 10% Sales Slide in 1st Half on Gilenya Royalty Row
October 31, 2019
-
Eisai Sees Brisk Sales of Global Brands, but Earnings Slump on One-Off Factors
October 31, 2019
-
Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings
October 31, 2019
-
Taisho’s Prescription Drug Sales Suffer Double-Digit Decline in H1, due to Capital Tie-Up Dissolution with Toyama Chemical
October 31, 2019
-
To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…